GSK plc (NYSE:GSK) Getting Ahead of Respiratory Diseases Event with GSK Management Conference Call November 30, 2023 8:00 AM ET Company Participants Nick Stone - Investor Relations Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Richard Parkes - BNP Paribas Andrew Baum - Citi Peter Welford - Jefferies Seamus Fernandez - Guggenheim Kerry Holford - Berenberg Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Nick Ston ...

GSK plc (NYSE:GSK) Redburn Atlantic CEO Conference November 29, 2023 4:00 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Simon Baker Good morning, and good afternoon, everybody. My name is Simon Baker from the Redburn Atlantic biopharma team. It is our great pleasure to introduce Luke Miels, the Chief Commercial Officer for GSK. Luke thanks very much for participating. Question-and-Answer Session Q - Simon Baker We'll move straight into Q& ...

GSK plc (NYSE:GSK) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 7:30 AM ET Company Participants Jeff McLaughlin - Director, Investor Relations Philip Dormitzer - SVP and Global Head, Vaccines R&D and Infectious Disease Research Conference Call Participants Umer Raffat - Evercore ISI Jessica Hui - Evercore ISI Umer Raffat Good morning, everyone. Thank you for joining us, our Day 2, and, I am really excited to kick the day off with our friends from GSK. There is a lot to talk about, in part ...

Company Participants Conference Call Participants Nick Stone The presentation was sent out to our distribution list by email. And you can also find us on gsk.com. Please turn to Slide 3. Today's call will last approximately one hour with the management presentation taking around 30 minutes and the remaining time for your questions. [Operator Instructions] I'll now hand the call over to Emma. Thanks, Nick, and welcome to everybody joining us today. Sales and profits grew double-digits for the quarter, with s ...

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or For ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_a16359064f30ce4fa5335afb84717c24.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_04fd72ee42938857e3146e9d4b58af85.html ...

Straight to you, Julie. Okay. Thank you very much. Thanks James. So, in terms of -- I see a competitive P&L as one that's operating to full capacity and making optimal use of the resources in the business and capital allocation in the business. And I think good progress has been made in GSK already following the separation with the future ready program. And working with Tony closely because, obviously, I've been in the pharma industry for a long time and worked with R&D for a long time. Clearly, investment ...

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Rep ...